research digest // gh-secretagogue stack
CJC-1295 Ipamorelin is a long-acting GHRH analogue fired alongside a selective GHRP — studied as a synergistic growth-hormone-secretagogue stack.
Two receptors. Two pathways. One amplified GH pulse — larger than the sum. Here is what the literature actually measured, and where it goes quiet.
TL;DR
CJC-1295 Ipamorelin is two lab peptides used together. CJC-1295 is a long-acting copy of GHRH (the natural hormone that tells the pituitary gland to release growth hormone). Ipamorelin is a GHRP (a peptide that hits a second switch on the same gland — the ghrelin receptor). Each one alone raises growth hormone (GH). Fired together, they push a bigger GH pulse than either does on its own — the studies call this "synergy" (a combined effect larger than the two added up).
In healthy adults, a single CJC-1295 dose raised GH 2- to 10-fold for six days or more [1]. The combination's downstream story — better sleep, faster recovery, slow body-composition change — is partly measured in single peptides and partly extrapolated. Neither peptide is FDA-approved, and the fixed blend has never been tested in a controlled trial. What people report — including the downsides — is on the effects page.
Cjc ipamorelin
The pairing is built on a thirty-year-old finding. In normal men, a submaximal GHRP dose combined with GHRH stimulated GH release synergistically — the two acting through independent mechanisms [3]. That is the entire rationale in one sentence: two doors into the same room, opened at once, let more through than the sum of each opened alone.
CJC-1295 works the GHRH door. It binds the GHRH receptor on the pituitary's GH-making cells (somatotrophs), raising cAMP and driving GH synthesis and release [5]. Ipamorelin works the ghrelin door. It binds GHS-R1a (the ghrelin receptor) on the same cells, raising intracellular calcium [2]. At the receptor level, co-activating both produced roughly twice the cAMP signal of the GHRH receptor alone [4]. Different switches, one output, amplified.
The numbers that anchor the stack
Most of the hard data is single-component. Treat it as the floor, not the blend.
- CJC-1295 (with DAC): one subcutaneous dose raised mean plasma GH 2- to 10-fold for 6+ days and IGF-1 1.5- to 3-fold for 9–11 days in healthy adults; after multiple doses IGF-1 stayed above baseline up to 28 days [1].
- Ipamorelin: the first selective GH secretagogue — it released GH as well as older GHRPs but did not raise ACTH or cortisol above GHRH-stimulated levels even at doses over 200× the dose needed for GH release [2]. That selectivity is its signature.
- The synergy: demonstrated in humans for a GHRP + GHRH pairing [3] and at the receptor level in transfected cells [4].
The cjc 1295 dac form and the no-DAC mod grf 1-29 form sit on very different timescales — that distinction is its own page each.
What it does not say
Read the gap as carefully as the data. There is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295 + ipamorelin combination itself. Every combination claim rests on (a) each peptide's own literature and (b) general GHRH+GHRP synergy work done with related peptides — not this exact pair [3][4]. The combination has never been tested as a fixed blend in a controlled clinical trial.
Neither component is FDA-approved for any human use [6]. Both are WADA-prohibited at all times under Section S2. The stack raises GH and IGF-1 — that much is cited; downstream muscle gain and fat loss in humans are extrapolated, not established. This site is CJC-1295 Ipamorelin research, logged to source. It sells nothing.